Clinical characteristics of Candida tropicalis fungaemia with reduced triazole susceptibility in Taiwan: a multicentre study.

[1]  Yun-Liang Yang,et al.  The distribution and drug susceptibilities of clinical Candida species in TSARY 2014. , 2016, Diagnostic microbiology and infectious disease.

[2]  M. Castanheira,et al.  Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). , 2016, Diagnostic microbiology and infectious disease.

[3]  J. Sobel,et al.  Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Chakrabarti,et al.  Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  J. Guinea,et al.  Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance. , 2015, The Journal of infection.

[6]  H. Kantarjian,et al.  The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. , 2015, The Journal of antimicrobial chemotherapy.

[7]  M. Bassetti,et al.  Clinical and Therapeutic Aspects of Candidemia: A Five Year Single Centre Study , 2015, PloS one.

[8]  W. Ricciardi,et al.  Antifungal Susceptibility Profiles of Bloodstream Yeast Isolates by Sensititre YeastOne over Nine Years at a Large Italian Teaching Hospital , 2015, Antimicrobial Agents and Chemotherapy.

[9]  Chih-Cheng Lai,et al.  Epidemiology and Prognostic Factors of Candidemia in Cancer Patients , 2014, PloS one.

[10]  J. Guinea.  Global trends in the distribution of Candida species causing candidemia. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  J. Pemán,et al.  Impact of Therapeutic Strategies on the Prognosis of Candidemia in the ICU* , 2014, Critical care medicine.

[12]  C. Liao,et al.  Antifungal Susceptibilities of Candida Isolates Causing Bloodstream Infections at a Medical Center in Taiwan, 2009-2010 , 2014, Antimicrobial Agents and Chemotherapy.

[13]  A. Fothergill,et al.  Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species , 2014, Journal of Clinical Microbiology.

[14]  R. Wenzel,et al.  Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. , 2014, International journal of antimicrobial agents.

[15]  C. Pina-Vaz,et al.  Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole for Six Candida Species as Determined by the Colorimetric Sensititre YeastOne Method , 2013, Journal of Clinical Microbiology.

[16]  J. Sobel,et al.  Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Mariana Henriques,et al.  Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. , 2012, FEMS microbiology reviews.

[18]  A. Wang,et al.  The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. , 2010, Medical mycology.

[19]  Yu-Hsin Lin,et al.  Two closely related fluconazole-resistant Candida tropicalis clones circulating in Taiwan from 1999 to 2006. , 2009, Microbial drug resistance.